Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

689 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MET DNA Alterations in NSCLC-Letter.
Mengoli MC, Bertolini F, Tiseo M, Barbieri F, Fiorentino M, Ardizzoni A, Rossi G. Mengoli MC, et al. Among authors: barbieri f. Clin Cancer Res. 2016 Jul 15;22(14):3697-8. doi: 10.1158/1078-0432.CCR-16-0351. Clin Cancer Res. 2016. PMID: 27422202 No abstract available.
Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial.
Landi L, Chiari R, Tiseo M, D'Incà F, Dazzi C, Chella A, Delmonte A, Bonanno L, Giannarelli D, Cortinovis DL, de Marinis F, Borra G, Morabito A, Gridelli C, Galetta D, Barbieri F, Grossi F, Capelletto E, Minuti G, Mazzoni F, Verusio C, Bria E, Alì G, Bruno R, Proietti A, Fontanini G, Crinò L, Cappuzzo F. Landi L, et al. Among authors: barbieri f. Clin Cancer Res. 2019 Dec 15;25(24):7312-7319. doi: 10.1158/1078-0432.CCR-19-0994. Epub 2019 Aug 15. Clin Cancer Res. 2019. PMID: 31416808 Clinical Trial.
Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients.
Reale ML, Chiari R, Tiseo M, Vitiello F, Barbieri F, Cortinovis D, Ceresoli GL, Finocchiaro G, Romano GD, Piovano PL, Del Conte A, Borra G, Verderame F, Scotti V, Nonnis D, Galetta D, Sergi C, Migliorino MR, Tonini G, Cecere F, Berardi R, Pino MS, Martelli O, Gelibter A, Carta A, Vattemi E, Pagano M, Zullo A, Ferrari S, Rossi A, Novello S. Reale ML, et al. Among authors: barbieri f. Lung Cancer. 2020 Feb;140:71-79. doi: 10.1016/j.lungcan.2019.12.006. Epub 2019 Dec 16. Lung Cancer. 2020. PMID: 31884129
Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study.
Pilotto S, Rossi A, Vavalà T, Follador A, Tiseo M, Galetta D, Morabito A, Di Maio M, Martelli O, Caffo O, Piovano PL, Cortinovis D, Zilembo N, Casartelli C, Banna GL, Ardizzoia A, Barzelloni ML, Bearz A, Genestreti G, Mucciarini C, Filipazzi V, Menis J, Rizzo E, Barbieri F, Rijavec E, Cecere F, Spitaleri G, Bria E, Novello S. Pilotto S, et al. Among authors: barbieri f. Clin Lung Cancer. 2018 Jan;19(1):93-104. doi: 10.1016/j.cllc.2017.05.016. Epub 2017 Jun 1. Clin Lung Cancer. 2018. PMID: 28645631
Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program.
Garassino MC, Crinò L, Catino A, Ardizzoni A, Cortesi E, Cappuzzo F, Bordi P, Calabrò L, Barbieri F, Santo A, Altavilla G, Ambrosio F, Mini E, Vasile E, Morgillo F, Scoppola A, Bengala C, Follador A, Tedde N, Giannarelli D, Lo Russo G, Vitiello F. Garassino MC, et al. Among authors: barbieri f. Tumour Biol. 2018 Nov;40(11):1010428318815047. doi: 10.1177/1010428318815047. Tumour Biol. 2018. PMID: 30486741 Free article.
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status.
Facchinetti F, Mazzaschi G, Barbieri F, Passiglia F, Mazzoni F, Berardi R, Proto C, Cecere FL, Pilotto S, Scotti V, Rossi S, Del Conte A, Vita E, Bennati C, Ardizzoni A, Cerea G, Migliorino MR, Sala E, Camerini A, Bearz A, De Carlo E, Zanelli F, Guaitoli G, Garassino MC, Ciccone LP, Sartori G, Toschi L, Dall'Olio FG, Landi L, Pizzutilo EG, Bartoli G, Baldessari C, Novello S, Bria E, Cortinovis DL, Rossi G, Rossi A, Banna GL, Camisa R, Di Maio M, Tiseo M. Facchinetti F, et al. Among authors: barbieri f. Eur J Cancer. 2020 May;130:155-167. doi: 10.1016/j.ejca.2020.02.023. Epub 2020 Mar 25. Eur J Cancer. 2020. PMID: 32220780
Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL).
Gelsomino F, Tiseo M, Barbieri F, Riccardi F, Cavanna L, Frassoldati A, Delmonte A, Longo L, Dazzi C, Cinieri S, Colantonio I, Sperandi F, Lamberti G, Brocchi S, Tofani L, Boni L, Ardizzoni A. Gelsomino F, et al. Among authors: barbieri f. Br J Cancer. 2020 Jul;123(1):26-32. doi: 10.1038/s41416-020-0845-3. Epub 2020 Apr 29. Br J Cancer. 2020. PMID: 32346071 Free PMC article. Clinical Trial.
Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial.
Ardizzoni A, Tiseo M, Boni L, Vincent AD, Passalacqua R, Buti S, Amoroso D, Camerini A, Labianca R, Genestreti G, Boni C, Ciuffreda L, Di Costanzo F, de Marinis F, Crinò L, Santo A, Pazzola A, Barbieri F, Zilembo N, Colantonio I, Tibaldi C, Mattioli R, Cafferata MA, Camisa R, Smit EF. Ardizzoni A, et al. Among authors: barbieri f. J Clin Oncol. 2012 Dec 20;30(36):4501-7. doi: 10.1200/JCO.2012.43.6758. Epub 2012 Oct 29. J Clin Oncol. 2012. PMID: 23109689 Clinical Trial.
689 results